|
|
| Line 2: |
Line 2: |
| {{Follicular lymphoma}} | | {{Follicular lymphoma}} |
|
| |
|
| {{CMG}}; {{AE}} {{AS}}
| | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. |
| ==Overview==
| |
| | |
| There are a large number of recent and current clinical trials for follicular lymphoma. Personalised idiotype vaccines have shown promise, but have still to prove their efficacy in randomized clinical trials.
| |
| | |
| ==Future or Investigational therapies==
| |
| Personalised idiotype vaccines have shown promise, but have still to prove their efficacy in randomized clinical trials.<ref>{{cite journal |author=Inoges S, de Cerio AL, Soria E, Villanueva H, Pastor F, Bendandi M |title=Idiotype vaccines for human B-cell malignancies |journal=Curr. Pharm. Des. |volume=16 |issue=3 |pages=300–7 |date=January 2010 |pmid=20109139 |doi= 10.2174/138161210790170111|url=http://www.benthamdirect.org/pages/content.php?CPD/2010/00000016/00000003/0006B.SGM}}</ref>
| |
| | |
| In 2010 [[Rituximab]] was approved by the EC for first-line maintenance treatment of follicular lymphoma.<ref>{{cite news |url=http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/ |title=Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy |date=October 29, 2010 }}</ref> Pre-clinical evidence suggests that rituximab could be also used in combination with integrin inhibitors to overcome the resistance to rituximab mediated by stromal cells .<ref>{{Cite journal | last1 = Mraz | first1 = M. | last2 = Zent | first2 = C. S. | last3 = Church | first3 = A. K. | last4 = Jelinek | first4 = D. F. | last5 = Wu | first5 = X. | last6 = Pospisilova | first6 = S. | last7 = Ansell | first7 = S. M. | last8 = Novak | first8 = A. J. | last9 = Kay | first9 = N. E. | last10 = Witzig | doi = 10.1111/j.1365-2141.2011.08794.x | first10 = T. E. | last11 = Nowakowski | first11 = G. S. | title = Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance | journal = British Journal of Haematology | volume = 155 | issue = 1 | pages = 53–64 | year = 2011 | pmid = 21749361 | pmc = }}</ref> However, follicular lymphoma which is CD20 negative will not benefit from Rituximab which targets CD20.
| |
| | |
| Trial results released in June 2012 show that [[bendamustine]], a drug first developed in East Germany in the 1960s, more than doubled disease progression-free survival when given along with [[rituximab]]. The combination also left patients with fewer side effects than the older treatment (a combination of five drugs—rituximab, cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine and prednisone, collectively called [[R-CHOP]]).<ref>{{cite news |url=http://health.usnews.com/health-news/news/articles/2012/06/03/rediscovered-lymphoma-drug-helps-double-survival-study|title='Rediscovered' Lymphoma Drug Helps Double Survival: Study |date=June 3, 2012 }}</ref>
| |
| | |
| There are a large number of recent and current clinical trials for follicular lymphoma.<ref>http://clinicaltrials.gov/ct2/results?term=follicular+lymphoma</ref>
| |
| | |
| | |
| | |
|
| |
|
| ==References== | | ==References== |
| {{reflist|2}} | | {{Reflist|2}} |
| | |
| | |
|
| |
|
| | [[Category:Needs content]] |
| [[Category:Hematology]] | | [[Category:Hematology]] |
| [[Category:Types of cancer]] | | [[Category:Types of cancer]] |